 Osmotica will receive a 110 million upfront cash payment, with the potential to receive up to 60 million in additional milestone payments Alora will acquire manufacturing operations in Marietta, Georgia in addition to legacy products Osmotica will retain the RVL Pharmaceuticals business focused on ophthalmology and aesthetics, led by its flagship product, UPNEEQ Osmotica will also retain arbaclofen extended-release ER tablets in development to treat Multiple Sclerosis MS spasticity Conference call to be held at 8:30 a.m. ET 